Avicenna journal of phytomedicine · 2024
Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amin Mansour, Pouladzadeh Mandana, Yadyad Mohammad Jaafar, Roshanfard Roshanak, Pipelzadeh Mohamad Hasan, Talebi Afshin, Sharif Maakhmalzadeh Behzad, Bijanzadeh Mehdi, Rakipour Nasrin, Alizadehattar Gholamreza, Seyedian Seyed Saeed, Ahmadi Angali Kambiz, Moradi Choghakabodi Parastoo, Akbari Akbar, Maghsodi Fatemeh, Barzegari Ebrahim, Jamalan Maryam, Aalizadeh Reza, Jamalan Mostafa
Аннотация
OBJECTIVE: Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.
MATERIALS AND METHODS: We assessed effect of shallomin oral syrup (co IranAmin®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.
RESULTS: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.
CONCLUSION: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.
MATERIALS AND METHODS: We assessed effect of shallomin oral syrup (co IranAmin®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.
RESULTS: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.
CONCLUSION: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.